Dominic Piscitelli Sells 52,000 Shares of Oric Pharmaceuticals (NASDAQ:ORIC) Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli sold 52,000 shares of the stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $13.51, for a total value of $702,520.00. Following the completion of the transaction, the chief financial officer directly owned 68,148 shares in the company, valued at approximately $920,679.48. This represents a 43.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Dominic Piscitelli also recently made the following trade(s):

• On Tuesday, December 16th, Dominic Piscitelli sold 10,720 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $9.06, for a total value of $97,123.20.

Oric Pharmaceuticals Price Performance

NASDAQ ORIC traded up $0.10 on Thursday, reaching $13.50. 1,043,043 shares of the company’s stock traded hands, compared to its average volume of 1,709,341. The stock has a market cap of $1.35 billion, a PE ratio of -8.88 and a beta of 1.35. Oric Pharmaceuticals, Inc. has a 12 month low of $3.90 and a 12 month high of $14.93. The stock has a 50-day simple moving average of $10.17 and a 200 day simple moving average of $10.96.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04. As a group, analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current year.

Trending Headlines about Oric Pharmaceuticals

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: Q4 earnings beat consensus (reported EPS -$0.30 vs. -$0.34 expected), which likely sparked buyer interest and helped lift the stock. Read More.
• Positive Sentiment: HC Wainwright raised Q1–Q4 and FY2026 EPS estimates (improving loss trajectory) and reiterated a Buy with a $25 price target (up from $23), giving investors a higher valuation anchor. This analyst upgrade and estimate lift are supportive for further upside. Read More.
• Positive Sentiment: Broker consensus/coverage implies significant upside — a Zacks compilation notes the mean analyst price target implies roughly ~58% upside, which can attract momentum buying from growth/biotech investors. Read More.
• Positive Sentiment: Wedbush issued an Outperform rating, adding to the positive analyst momentum behind the shares. Read More.
• Neutral Sentiment: Recent market writeups reassessing ORIC after Phase 1b data and a $264M capital raise discuss valuation and runway; the capital raise reduces near‑term financing risk but may be dilutionary — investors will parse data and dilution when setting targets. Read More.
• Negative Sentiment: CFO Dominic Piscitelli sold 52,000 shares (~43% reduction in his holdings) at ~$13.51 per share, a sizable insider sale that can cause concern for some investors about timing or liquidity needs. The transaction is disclosed in the SEC filing. Read More.

Institutional Trading of Oric Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC increased its position in Oric Pharmaceuticals by 17,300.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,436 shares of the company’s stock valued at $25,000 after purchasing an additional 2,422 shares during the period. Federation des caisses Desjardins du Quebec boosted its stake in shares of Oric Pharmaceuticals by 100.0% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock valued at $33,000 after purchasing an additional 2,000 shares in the last quarter. Assetmark Inc. purchased a new position in shares of Oric Pharmaceuticals during the third quarter valued at about $37,000. Caitong International Asset Management Co. Ltd raised its stake in Oric Pharmaceuticals by 184.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock worth $37,000 after buying an additional 2,936 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Oric Pharmaceuticals by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock worth $39,000 after buying an additional 977 shares in the last quarter. Institutional investors own 95.05% of the company’s stock.

Analysts Set New Price Targets

ORIC has been the subject of a number of recent research reports. Oppenheimer reissued an “outperform” rating and issued a $15.00 target price on shares of Oric Pharmaceuticals in a research note on Tuesday. HC Wainwright boosted their price objective on Oric Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday. Wolfe Research began coverage on Oric Pharmaceuticals in a research note on Tuesday, November 18th. They set a “peer perform” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Thursday, January 22nd. Finally, JPMorgan Chase & Co. upped their price target on shares of Oric Pharmaceuticals from $17.00 to $20.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Oric Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $20.20.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.